PATENT CLAIM ANALYSIS

Application Number: 15778368
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["424", "218100"]

Abstract:
A highly safe dengue vaccine was invented that induced a neutralizing antibody response against all of the four serotypes of dengue virus without developing more than a fixed level of viremia with single administration. A tetravalent dengue virus formulation is provided that is excellent in both efficacy (neutralizing antibody response) and safety (viremia).

Claim (Index 31):
An attenuated serotype 4 dengue virus wherein said virus has homology of 95% or more with serotype 4 dengue virus parent strain 1036 having an amino acid sequence of SEQ ID NO: 4 as analyzed using a Next Generation Sequencer, has complete mutation at amino acid residue at position 2187 or 2354 of said parent strain, and further has no mutation at position 624, 742, 1628, 2286, 2482 or 2508.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 93.0
- Lexical Diversity: 1.37209
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15195820', '11449876', '11453344', '13212845', '13281240']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7413961328025707
- 35 USC 102 Novelty (BERT): 0.5441846686975823
- Combined Prediction Score: 0.7216749863920718
- Mean Citation Score: 370.044854
- Max Citation Score: 379.45105
- Similarity Product: 286.8586090986521

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test